Kircik Leon H
J Drugs Dermatol. 2014 May;13(5):582-5.
Dysfunction of the epidermal barrier is generally considered a precursor of cutaneous inflammation that can directly contribute to the pathogenesis of skin diseases, notably atopic dermatitis (AD). We also know that topical corticosteroids may actually impair the epidermal barrier by interfering with epidermal lipid synthesis. Therefore, it is important to utilize topical corticosteroids in vehicles that will help at least to enhance the already disrupted epidermal barrier in atopic dermatitis patients. Two studies of identical design were conducted to determine and compare the occlusivity and moisturizing potential of three topical corticosteroid products when applied to skin whose barrier integrity has been disrupted by dry shaving. Findings in both studies showed the clocortolone pivalate cream decreased TEWL better than non-treatment or treatment with hydrocortisone butyrate lotion. Skin surface hydration increased significantly (P<0.001) in all three treated sites, compared to the non-treated damaged control and non-treated normal skin. Clocortolone pivalate cream increased skin surface hydration significantly (P<0.001) better than hydrocortisone butyrate lipocream or hydrocortisone butyrate lotion. These studies showed that clocortolone pivalate cream enhances barrier function by providing occlusion. While understanding of the structure and function of the stratum corneum (SC) and epidermal barrier function has evolved tremendously over the last several decades, and especially over the last 15 years,1 confusion and misinformation still persist. Dysfunction of the epidermal barrier is generally considered a precursor of cutaneous inflammation that can directly contribute to the pathogenesis of skin diseases, notably atopic dermatitis (AD).2,3 Topical steroids are standard of care in treatment of atopic dermatitis. However, we also know that topical corticosteroids may actually impair epidermal barrier by interfering with epidermal lipid synthesis.4,5 In addition to that, various penetration enhancers in the topical steroid formulations also contribute to the impairment of the epidermal barrier.4 Therefore, it is important to utilize topical corticosteroids in vehicles that will help at least to enhance the already disrupted epidermal barrier in atopic dermatitis patients. In this regard, these studies were designed to determine the hydrating effects of clocortolone pivalate cream 0.1% (Cloderm Cream, Promius Pharma).
表皮屏障功能障碍通常被认为是皮肤炎症的先兆,可直接促使皮肤病尤其是特应性皮炎(AD)的发病。我们也知道,局部用皮质类固醇实际上可能通过干扰表皮脂质合成而损害表皮屏障。因此,在载体中使用局部用皮质类固醇很重要,这至少有助于增强特应性皮炎患者本已受损的表皮屏障。我们进行了两项设计相同的研究,以确定和比较三种局部用皮质类固醇产品应用于因干剃而破坏屏障完整性的皮肤时的封闭性和保湿潜力。两项研究的结果均显示,与不治疗或用丁酸氢化可的松洗剂治疗相比,特戊酸氯可托龙乳膏能更好地降低经皮水分流失(TEWL)。与未治疗的受损对照和未治疗的正常皮肤相比,所有三个治疗部位的皮肤表面水合作用均显著增加(P<0.001)。特戊酸氯可托龙乳膏使皮肤表面水合作用显著增加(P<0.001),优于丁酸氢化可的松脂质乳膏或丁酸氢化可的松洗剂。这些研究表明,特戊酸氯可托龙乳膏通过提供封闭作用来增强屏障功能。虽然在过去几十年,尤其是过去15年中,人们对角质层(SC)的结构和功能以及表皮屏障功能的理解有了巨大进展,但混乱和错误信息仍然存在。表皮屏障功能障碍通常被认为是皮肤炎症的先兆,可直接促使皮肤病尤其是特应性皮炎(AD)的发病。局部用类固醇是治疗特应性皮炎的标准疗法。然而,我们也知道,局部用皮质类固醇实际上可能通过干扰表皮脂质合成而损害表皮屏障。此外,局部用类固醇制剂中的各种渗透促进剂也会导致表皮屏障受损。因此,在载体中使用局部用皮质类固醇很重要,这至少有助于增强特应性皮炎患者本已受损的表皮屏障。在这方面, 这些研究旨在确定0.1%特戊酸氯可托龙乳膏(Cloderm乳膏,Promius制药公司)的保湿效果。